The following represents disclosure information provided by authors of this abstract. The ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Elevated pretreatment serum activin A and progression-free and overall survival in trastuzumab-treated metastatic breast cancer.
Lindsey Zubritsky
No relevant relationships to disclose
Kim Leitzel
Research Funding - Celgene
Suhail M. Ali
No relevant relationships to disclose
Wolfgang Köstler
No relevant relationships to disclose
Eva-Maria Fuchs
No relevant relationships to disclose
Luis Costa
No relevant relationships to disclose
Robert D. Knight
Employment or Leadership Position - Celgene
Abderrahmane Laadem
Employment or Leadership Position - Celgene
Matthew L. Sherman
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Allan Lipton
Research Funding - Celgene